ZURICH (Reuters) – Roche’s Gavreto has won conditional European Commission approval for treating adults with a form of non-small cell lung cancer, the Swiss drugmaker said on Friday.
Gavreto, known generically as pralsetinib, is the first and only precision medicine approved in the EU for first-line treatment of people with RET fusion-positive advanced NSCLC. Around 37,500 people are diagnosed with RET fusion-positive NSCLC worldwide each year, it said https://www.roche.com/media/releases/med-cor-2021-11-19.htm in a statement.
(Reporting by Michael Shields; Editing by Riham Alkousaa)
